Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease

Ly, Milovanova; Ys, Milovanov; Dv, Kudryavtseva; Mm, Markina; Sy, Milovanova; Lv, Kozlovskaya; Mv, Lebedeva; Beketov, Vladimir; Moiseev, Sergey; Na, Mukhin; Vv, Fomin; Aa, Svistunov

doi:10.17116/terarkh201587610-16

Cited by 8 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adequate sKlotho expression provides both renal and CV protection. According to our date [31], patients from third stage of CKD have shown a direct linear relation between GFR fall and decreasing in sKlotho level. As it was detected firstly by M. Kuro-o, Klotho is synthesized in kidney tubules.…”

Section: Klotho and Anemia In Chronic Kidney Diseasementioning

confidence: 89%

Anemia in Chronic Kidney Disease and After Kidney Allotransplantation (Systematic Review)

Milovanov¹,

Lysenko²,

Milоvаnоvа³

et al. 2018

Current Topics in Anemia

View full text Add to dashboard Cite

Anemia in chronic kidney disease (CKD) has been recognized as a separate independent risk factor of cardiovascular (CV) events. The aim of the review is to provide a literature summary concerning early diagnosis and treatment of anemia in CKD that may be useful for clinicians and contribute to decrease CV mortality. Literature searches were made in such major databases as: PubMed, Medline, Embase, Cochrane Library, CINAHL, Wiley Online Library, Scopus, Web of Science, e-library, and website of WHO. This search encompassed original articles, systematic reviews, and meta-analyses relevant to CKD and anemia over recent 15 years. A total of 54 references from 562 reviewed articles were selected as they met to the search criteria (anemia and CKD, including diabetes mellitus, systemic diseases and post-transplant anemia). The publications included 27 randomized controlled trials, 20 experimental studies representing new data on the links of CKD anemia and cardiovascular risk markers (cytokines, Klotho, fibroblast growth factor (FGF-23), hyperglycemia, hypoalbuminemia and some others), 4 systematic reviews and 3 clinical practice guidelines. The main attention was devoted to the analysis of the studies provided an early diagnosis of anemia, an ability to minimize the factors contributing to its severity that have allowed to improve CV and total outcomes and to reduce costs of hospital treatment of CKD patients with anemia.

show abstract

Section: Klotho and Anemia In Chronic Kidney Diseasementioning

confidence: 89%

Anemia in Chronic Kidney Disease and After Kidney Allotransplantation (Systematic Review)

Milovanov¹,

Lysenko²,

Milоvаnоvа³

et al. 2018

Current Topics in Anemia

View full text Add to dashboard Cite

show abstract

“…(2014), в котором замедление СКФ ассоциировалось с достоверным повышением в плазме уровня фибропластического фактора роста 23-го типа (FGF-23) и ростом распространенности ГЛЖ [35]. В другом одномоментном исследовании показано, что концентрация FGF-23 повышается уже при ХБП III стадии [36]. При этом прямая связь между повышением уровня FGF-23 и увеличением ММЛЖ была наиболее выраженной у пациентов с артериальной гипертензией.…”

Section: разное §unclassified

Relationship of Remodeling of Carotid Arteries and Left Ventricular Geometry in Patients With Chronic Glomerulonephritis

Муркамилов

Айтбаев

Sarybaev

et al. 2018

CARDIO

Self Cite

View full text Add to dashboard Cite

“…FGF23 causes reversible hypertrophy of cardiac myocytes in mice [ 14 ] and in myocardial autopsy samples from dialysis patients [ 15 ]. High levels of FGF23 are positively correlated with increasing blood pressure [ 16 ] and pulse pressure [ 17 ] in CKD, this may be due to impairment of endothelial dependent vasorelaxation [ 18 ], High levels of FGF23 are associated with arterial stiffness [ 19 ], atherosclerosis [ 19 , 20 ] and aortic valve calcifications [ 21 ] in CKD. FGF23 can directly stimulate the hepatic production of inflammatory cytokines such as C reactive protein [ 22 ].…”

Section: Introductionmentioning

confidence: 99%

Longitudinal change in c-terminal fibroblast growth factor 23 and outcomes in patients with advanced chronic kidney disease

et al. 2021

View full text Add to dashboard Cite

Background Fibroblast growth factor23 (FGF23) is elevated in CKD and has been associated with outcomes such as death, cardiovascular (CV) events and progression to Renal Replacement therapy (RRT). The majority of studies have been unable to account for change in FGF23 over time and those which have demonstrate conflicting results. We performed a survival analysis looking at change in c-terminal FGF23 (cFGF23) over time to assess the relative contribution of cFGF23 to these outcomes. Methods We measured cFGF23 on plasma samples from 388 patients with CKD 3-5 who had serial measurements of cFGF23, with a mean of 4.2 samples per individual. We used linear regression analysis to assess the annual rate of change in cFGF23 and assessed the relationship between time-varying cFGF23 and the outcomes in a cox-regression analysis. Results Across our population, median baseline eGFR was 32.3mls/min/1.73m2, median baseline cFGF23 was 162 relative units/ml (RU/ml) (IQR 101-244 RU/mL). Over 70 months (IQR 53-97) median follow-up, 76 (19.6%) patients progressed to RRT, 86 (22.2%) died, and 52 (13.4%) suffered a major non-fatal CV event. On multivariate analysis, longitudinal change in cFGF23 was significantly associated with risk for death and progression to RRT but not non-fatal cardiovascular events. Conclusion In our study, increasing cFGF23 was significantly associated with risk for death and RRT.

show abstract

Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease

Cited by 8 publications

References 18 publications

Anemia in Chronic Kidney Disease and After Kidney Allotransplantation (Systematic Review)

Anemia in Chronic Kidney Disease and After Kidney Allotransplantation (Systematic Review)

Relationship of Remodeling of Carotid Arteries and Left Ventricular Geometry in Patients With Chronic Glomerulonephritis

Longitudinal change in c-terminal fibroblast growth factor 23 and outcomes in patients with advanced chronic kidney disease

Contact Info

Product

Resources

About